Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.8 USD | +0.38% | -6.84% | -11.98% |
09/05 | UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating | MT |
08/05 | Transcript : REGENXBIO Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.98% | 78Cr | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.22TCr | |
-3.26% | 2.13TCr | |
-5.66% | 1.9TCr | |
-35.21% | 1.85TCr | |
-10.86% | 1.68TCr | |
+37.57% | 1.25TCr | |
-26.24% | 808.97Cr |
- Stock Market
- Equities
- RGNX Stock
- News REGENXBIO Inc.
- Wedbush Lowers REGENXBIO's Price Target to $18 From $28, Notes Lack of Catalysts Over Next 12 Months; Keeps Neutral Rating